L'actif (L-Glutathion rduit), un agent de charge naturel (fibres d'acacia) et un antiagglomrant d'origine minrale (sels de magnsium d'acides gras)
No randomized controlled trial has evaluated CJC-1295 for body composition, bone density, or metabolic endpoints with the rigor expected of a Phase III program
New Insights and Promising Therapies Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials Effects of GLP-1 on ovarian dysfunction in polycystic ovary syndrome: A protocol for systematic review and meta-analysis These weight loss injections work by mimicking a hormone that regulates appetite and food intake
The Meteoric Rise of GLP-1 Utilization The impact of GLP-1s on Medicare spending is already remarkable
5- other GLP-1 trials in Parkinsons have been statistically negative or the results unclear, 6- the study was conducted in only very early Parkinsons cases, 7- the data, if replicable, may not be generalizable to all GLP-1 agonist drugs or to all subtypes of Parkinsons, and 8- the drug Lixisenatide requires a DAILY injection